Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Announces Discontinue Of Phase III ORIGIN Trial in Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia


Thursday, 18 Jul 2013 07:30am EDT 

Celgene Corporation announced that after consultation with the U.S. Food and Drug Administration (FDA) Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil. The FDA placed the ORIGIN study on clinical hold on July 12, 2013, with the discontinuation of lenalidomide treatment. All clinical investigators in ongoing chronic lymphocytic leukemia studies using lenalidomide will be officially advised of this action and instructed to inform their patients accordingly 

Company Quote

141.51
-0.35 -0.25%
17 Apr 2014